These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20624660)

  • 21. Mallory-Denk bodies: Correlation with steatosis, severity, zonal distribution, and identification with ubiquitin.
    Kayaçetin S; Başaranoğlu M
    Turk J Gastroenterol; 2015 Nov; 26(6):506-10. PubMed ID: 26507848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury.
    Hanada S; Strnad P; Brunt EM; Omary MB
    Hepatology; 2008 Sep; 48(3):943-52. PubMed ID: 18697208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between dietary total antioxidant capacity and hepatocellular ballooning in nonalcoholic steatohepatitis: a cross-sectional study.
    de Oliveira DG; de Faria Ghetti F; Moreira APB; Hermsdorff HHM; de Oliveira JM; de Castro Ferreira LEVV
    Eur J Nutr; 2019 Sep; 58(6):2263-2270. PubMed ID: 30019089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells.
    Di Cocco S; Belloni L; Nunn ADG; Salerno D; Piconese S; Levrero M; Pediconi N
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes.
    Schumacher-Petersen C; Christoffersen BØ; Kirk RK; Ludvigsen TP; Zois NE; Pedersen HD; Vyberg M; Olsen LH
    J Transl Med; 2019 Apr; 17(1):110. PubMed ID: 30943987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathology, grading and staging of nonalcoholic fatty liver disease.
    Kleiner DE
    Minerva Gastroenterol Dietol; 2018 Mar; 64(1):28-38. PubMed ID: 28948754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies.
    Vanderbeck S; Bockhorst J; Kleiner D; Komorowski R; Chalasani N; Gawrieh S
    Hum Pathol; 2015 May; 46(5):767-75. PubMed ID: 25776030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cytoskeleton in nonalcoholic steatohepatitis: 100 years old but still youthful.
    Molnar A; Haybaeck J; Lackner C; Strnad P
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):167-77. PubMed ID: 21476912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Interplay Between Sonic Hedgehog and Transforming Growth Factor-β1 in Human Nonalcoholic Steatohepatitis.
    Zhou X; Wang P; Ma Z; Li M; Teng X; Sun L; Wan G; Li Y; Guo L; Liu H
    Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):154-160. PubMed ID: 32044884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.
    Chalasani N; Wilson L; Kleiner DE; Cummings OW; Brunt EM; Unalp A;
    J Hepatol; 2008 May; 48(5):829-34. PubMed ID: 18321606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acidophil bodies in nonalcoholic steatohepatitis.
    Yeh MM; Belt P; Brunt EM; Kowdley KV; Wilson LA; Ferrell L;
    Hum Pathol; 2016 Jun; 52():28-37. PubMed ID: 26980020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross β-sheet conformation of keratin 8 is a specific feature of Mallory-Denk bodies compared with other hepatocyte inclusions.
    Mahajan V; Klingstedt T; Simon R; Nilsson KP; Thueringer A; Kashofer K; Haybaeck J; Denk H; Abuja PM; Zatloukal K
    Gastroenterology; 2011 Sep; 141(3):1080-1090.e1-7. PubMed ID: 21699779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Animal models of NAFLD from the pathologist's point of view.
    Denk H; Abuja PM; Zatloukal K
    Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):929-942. PubMed ID: 29746920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.
    Cansby E; Kulkarni NM; Magnusson E; Kurhe Y; Amrutkar M; Nerstedt A; Ståhlman M; Sihlbom C; Marschall HU; Borén J; Blüher M; Mahlapuu M
    FASEB J; 2019 Sep; 33(9):9974-9989. PubMed ID: 31173506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.